Genetic vulnerability of lung cancer to lay foundation for new drug options
DALLAS – April 4, 2013 – Physician-researchers at UT Southwestern Medical Center have identified a vulnerability of certain lung-cancer cells – a specific genetic weakness that can be exploited for new therapies.
Although researchers have long known that mutant versions of the KRAS gene drive tumor formation and are key to cell survival in non-small cell lung cancer, the blocking of activated KRAS has proven difficult. For years, investigations have explored stopping lung cancer at this junction, which also would have an impact on many other cancers. KRAS mutations, for ...